^
+ Follow HAL BARRON Tag
Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 639200
                    [Title] => Roche drugs plus chemotherapy significantly improve rate of complete tumor disappearance
                    [Summary] => 

TEXAS – Roche recently announced results from the NEOSPHERE trial, a Phase II neoadjuvant study evaluating the effect of a novel combination regimen of pertuzumab and trastuzumab plus chemotherapy in women with early-stage HER2-positive breast cancer.

[DatePublished] => 2010-12-16 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [1] => Array ( [ArticleID] => 628535 [Title] => Roche drug approved as first-line blood cancer maintenance treatment [Summary] =>

BASEL, Switzerland — Roche announced recently that the European Commission has approved the use of rituximab as a maintenance treatment for people suffering from follicular lymphoma, a common type of blood cancer, who have responded to initial induction therapy.

[DatePublished] => 2010-11-11 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) ) )
HAL BARRON
Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 639200
                    [Title] => Roche drugs plus chemotherapy significantly improve rate of complete tumor disappearance
                    [Summary] => 

TEXAS – Roche recently announced results from the NEOSPHERE trial, a Phase II neoadjuvant study evaluating the effect of a novel combination regimen of pertuzumab and trastuzumab plus chemotherapy in women with early-stage HER2-positive breast cancer.

[DatePublished] => 2010-12-16 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) [1] => Array ( [ArticleID] => 628535 [Title] => Roche drug approved as first-line blood cancer maintenance treatment [Summary] =>

BASEL, Switzerland — Roche announced recently that the European Commission has approved the use of rituximab as a maintenance treatment for people suffering from follicular lymphoma, a common type of blood cancer, who have responded to initial induction therapy.

[DatePublished] => 2010-11-11 00:00:00 [ColumnID] => 133272 [Focus] => 0 [AuthorID] => [AuthorName] => [SectionName] => Science and Environment [SectionUrl] => science-and-environment [URL] => ) ) )
abtest
Are you sure you want to log out?
X
Login

Philstar.com is one of the most vibrant, opinionated, discerning communities of readers on cyberspace. With your meaningful insights, help shape the stories that can shape the country. Sign up now!

Get Updated:

Signup for the News Round now

FORGOT PASSWORD?
SIGN IN
or sign in with